A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon alpha 2b and ribavirin treatment according to the stage of liver fibrosis in previously untreated patients with genotype 1/4/5/6 chronic hepatitis C (Practice)
Bourgeois, S; Deltenre, P; DELWAIDE, Jeanet al.
2014 • In Acta Gastro-Enterologica Belgica, 77, p. 393-400
DELWAIDE, Jean ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Henrion, J
Adler, M
Langlet, Ph
Mulkay, JP
Nevens, F
Brixko, C
Moreno, C
Language :
English
Title :
A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon alpha 2b and ribavirin treatment according to the stage of liver fibrosis in previously untreated patients with genotype 1/4/5/6 chronic hepatitis C (Practice)
Hatzakis A., Wait S., Bruix J., Buti M., Carballo M., Cavaleri M. et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J. Viral Hepat., 2011, 18 (Suppl 1): 1-16.
Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales J.R F.L. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 2002, 347: 975-982.
Hadziyannis S.J., Sette Jr H., Morga T.R., Balan V., Diago M., Marcellin P. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med., 2004, 140: 346-355.
Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358: 958-965.
Marrache F., Consigny Y., Ripault M.P., Cazals-Hatem D., Martinot M., Boyer N. et al. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J. Viral Hepat., 2005, 12: 421-428.
Abergel A., Hezode C., Leroy V., Barange K., Bronowicki J.P., Tran A. et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. J. Viral Hepat., 2006, 13: 811-820.
Roffi L., Colloredo G., Pioltelli P., Bellati G., Pozzpi M., Parravicini P. et al. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir. Ther., 2008, 13: 663-673.
Bruno S., Camma C., Di Marco V., Rumi M., Vinci M., Camozzi M. et al. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J. Hepatol., 2004, 41: 474-481.
Serfaty L., Aumaitre H., Chazouilleres O., Bonnand A.M., Rosmorduc O., Poupon R.E. et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology, 1998, 27: 1435-1440.
Benvegnu L., Gios M., Boccato S., Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut, 2004, 53: 744-749.
Fattovich G., Giustina G., Degos F., Tremolada F., Diodati G., Almasio P. et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology, 1997, 112: 463-472.
Shiratori Y., Ito Y., Yokosuka O., Imazeki F., Nakata R., Tanaka N. et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann. Intern. Med., 2005, 142: 105-114.
Bruno S., Stroffolini T., Colombo M., Bollani S., Benvegnu L., Mazzella G. et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology, 2007, 45: 579-587.
Veldt B.J., Heathcote E.J., Wedemeyer H., Reichen J., Hofmann W.P., Zeuzem S. et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann. Intern. Med., 2007, 147: 677-684.
Shiratori Y. Imazeki F., Moriyama M., Yano M., Arakawa Y., Yokosuka O. et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med., 2000, 132: 517-524.
Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z. et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology, 2002, 122: 1303-1313.
Beutels M., Van Damme P., Aelvoet W., Desmyter J., Dondeyne F., Goilav C. et al. Prevalence of hepatitis A, B and C in the Flemish population. Eur. J. Epid., 1997, 13: 275-280.
Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 1996, 24: 289-293.
